Related Experiment Videos
Ganglioside vaccines with emphasis on GM2
1Memorial Sloan-Kettering Cancer Center; and the Department of Medicine, Memorial Hospital, New York City, NY 10021, USA.
Seminars in Oncology
|December 29, 1998
Summary
Ganglioside vaccines targeting cancer cells show promise in immunotherapy. Clinical trials indicate that vaccines like GM2-KLH plus QS-21 are immunogenic and improve prognosis in melanoma patients.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Gangliosides are glycosphingolipids overexpressed in tumors of neuroectodermal origin, including melanoma.
- Gangliosides are effective targets for antibody-mediated immunotherapy, particularly in melanoma treatment.
Purpose of the Study:
- To evaluate the immunogenicity and efficacy of ganglioside-based vaccines in cancer immunotherapy.
- To assess the potential of ganglioside vaccines in improving patient prognosis for melanoma.
Main Methods:
- Development and testing of ganglioside-KLH conjugates (e.g., GM2-KLH, GD2, GMI, GD3) combined with QS-21 adjuvant.
- Clinical trials (Phase III) investigating the immune response and clinical outcomes in melanoma patients.
Main Results:
- Vaccination with GM2-KLH plus QS-21 demonstrated consistent immunogenicity and correlated with improved prognosis in AJCC stage III melanoma.
- Other ganglioside conjugates (GD2, fucosylated GMI, GD3-KLH) plus QS-21 also induced robust IgM and IgG antibody responses.
Conclusions:
- Ganglioside-based vaccines are a promising strategy for active immunotherapy in melanoma and potentially other cancers.
- Further clinical trials (Phase II and III) are planned for polyvalent ganglioside vaccines.